Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wyeth loses product liability suit

Executive Summary

Nevada jury finds that Wyeth's hormone replacement drugs Prempro and Premarin caused breast cancer in three women and awarded them a total of $134.5 million in compensatory damages. In its Oct. 10 verdict, the jury reportedly said Wyeth concealed a material fact about the safety of the drugs and acted with fraud and malice. The jury was to decide Oct. 12 if Wyeth should also pay punitive damages. The company has won six previous cases - three suits were dismissed, a judge overturned a jury verdict for plaintiffs in one case, and two resulted in verdicts for Wyeth (1"The Pink Sheet" July 9, 2007, p. 23). Approximately 5,200 suits have been filed in federal and state courts on behalf of about 8,400 women...

Nevada jury finds that Wyeth's hormone replacement drugs Prempro and Premarin caused breast cancer in three women and awarded them a total of $134.5 million in compensatory damages. In its Oct. 10 verdict, the jury reportedly said Wyeth concealed a material fact about the safety of the drugs and acted with fraud and malice. The jury was to decide Oct. 12 if Wyeth should also pay punitive damages. The company has won six previous cases - three suits were dismissed, a judge overturned a jury verdict for plaintiffs in one case, and two resulted in verdicts for Wyeth (1 'The Pink Sheet' July 9, 2007, p. 23). Approximately 5,200 suits have been filed in federal and state courts on behalf of about 8,400 women....

Latest Headlines
See All
UsernamePublicRestriction

Register

PS048898

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel